Executive Management

Christoph Westphal, M.D., Ph.D. Chairman/CEO Christoph Westphal, M.D., Ph.D. Chairman/CEO Dr. Westphal is a Partner of Longwood Founders Fund, which founds and invests in medical companies. He was founder and CEO of Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), which he took public and led as Chief Executive Officer until 2010. Dr. Westphal cofounded Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and was co-founder/CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Momenta Pharmaceuticals (NASDAQ: MNTA). Dr. Westphal serves on the board of direct...

Robert Forrester, LL.B. Chief Operating Officer Robert Forrester, LL.B. Chief Operating Officer Mr. Forrester has over 10 years experience as the CEO, COO or CFO of both private and public life science companies with Forma Therapeutics, CombinatoRx (NASDAQ: CRXX, now ZLCS) and Coley (NASDAQ: COLY, acquired by Pfizer). Robert was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks, BZW (now Barclays Capital) and UBS, in the corporate finance groups ...

Jonathan Pachter, Ph.D. Head of Research Jonathan Pachter, Ph.D. Head of Research Dr. Pachter brings over 20 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 - a selective...

Joanna Horobin, M.B., Ch.B. Chief Medical Officer Joanna Horobin, M.B., Ch.B. Chief Medical Officer Dr. Horobin has 30 years of pharmaceutical drug development experience. As President of Syndax Pharmaceuticals Dr. Horobin designed and implemented the phase 2 clinical development of Entinostat in metastatic breast and lung cancer. Formerly VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY), COO of CombinatoRx (NASDAQ: CRXX, now ZLCS) and EVP at EntreMed with experience spanning clinical development, marketing, and general management in both public and private companies. Dr. Horobin wa...

Dan Paterson Head of Corporate Development and Diagnostics Dan Paterson Head of Corporate Development and Diagnostics Mr. Paterson has over 20 years of experience in management roles at healthcare and biotechnology companies, including as COO and CEO, and specific expertise in oncology drug and diagnostic product development. Mr. Paterson was the founding CEO of The DNA Repair Company (acquired by On-Q-ity) which develops oncology-focused molecular diagnostics. Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health after playing a key role in the acquisition of PharMe...

Jack Green Chief Financial Officer Jack Green Chief Financial Officer Mr. Green was a key member of the senior management team for On-Q-ity and oversaw the financial activities, planning, budgeting and management of commercial and banking relationships. Previously, Mr. Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), which was spun out from Genzyme Corporation as a stand-alone public company. Mr. Green is a Certified Public Accountant (CPA) with over 30 years of financial experience,...